R. U. Varier, E. Biltaji, K. J. Smith, M. S. Roberts, M. K. Jensen, J

Slides:

Advertisements

Similar presentations

Microbial culturomics: paradigm shift in the human gut microbiome study J.-C. Lagier, F. Armougom, M. Million, P. Hugon, I. Pagnier, C. Robert, F. Bittar,

Advertisements

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012 M. Tvede,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

P.-Y. Lévy Clinical Microbiology and Infection

J.-C. Lagier Clinical Microbiology and Infection

The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection R. Singh, M. Nieuwdorp, I.J.M.

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Changes in the intestinal microbiota from adulthood through to old age

Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis J.

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection.

Migrant health—a cause for concern?

Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics Y.H. van Beurden, S. Nezami,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

U.S. Jensen, J.D. Knudsen, S. Wehberg, D.B. Gregson, K.B. Laupland

R. Cantón Clinical Microbiology and Infection

A.E. Muller, U. Theuretzbacher, J.W. Mouton

E. Cambau, M. Drancourt Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

E. Bouza Clinical Microbiology and Infection

Surveillance of Legionnaires’ disease in Austria

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection Sarah M. Bartsch, Craig A. Umscheid,

Vector control: a cornerstone in the malaria elimination campaign

E. Bouza, P. Muñoz, R. Alonso Clinical Microbiology and Infection

Training for the infectious diseases speciality in Norway

CMI editorial report 2011 Clinical Microbiology and Infection

B. Y. Lee, Z. S. Wettstein, S. M. McGlone, R. R. Bailey, C. A

The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study E. Manea, J. Sojo-Dorado, R.E. Jipa, S.N.

Levofloxacin in the treatment of ventilator-associated pneumonia

Mathematical modeling of Clostridium difficile infection

Metagenomics and probiotics

Laboratory diagnosis of Clostridium difficile disease

The economic burden of Clostridium difficile

The practice of travel medicine in Europe

T.M. File Clinical Microbiology and Infection

Long-term mortality following bloodstream infection

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Current experience in treating invasive zygomycosis with posaconazole

Vaccinations against respiratory tract infections at Hajj

Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013 U. Fedeli, E. Schievano,

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Microbiologic factors affecting Clostridium difficile recurrence

Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Z. Luo, Z. Fu, E. Liu, X. Xu, X. Fu, D. Peng,

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Diarrhoea in general practice: when should a Clostridium difficile infection be considered? Results of a nested case-control study M.P.M. Hensgens, O.M.

C.P. Kelly Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers

Modelling during an emergency: the 2009 H1N1 influenza pandemic

A. Manzur, F. Gudiol Clinical Microbiology and Infection

First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Three years experience of real-time PCR for the diagnosis of Q fever

Typing of Clostridium difficile

Great oaks from little acorns grow—21 years of CMI

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection R.U. Varier, E. Biltaji, K.J. Smith, M.S. Roberts, M.K. Jensen, J. LaFleur, R.E. Nelson Clinical Microbiology and Infection Volume 20, Issue 12, Pages 1343-1351 (December 2014) DOI: 10.1111/1469-0691.12805 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Model structure. FMT, faecal microbiota transplantation; RCDI, recurrent Clostridium difficile infection; AE, adverse effects of FMT. Clinical Microbiology and Infection 2014 20, 1343-1351DOI: (10.1111/1469-0691.12805) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 (a, b, c) Results, one-way sensitivity analysis. (a) Impact of changes in cost of FMT on overall cost per strategy. (b) Impact of changes in probability of CDI cure with FMT on overall cost per strategy. (c) Impact of changes in probability of CDI cure with FMT on overall effectiveness per strategy. Clinical Microbiology and Infection 2014 20, 1343-1351DOI: (10.1111/1469-0691.12805) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 3 Tornado diagram, FMT vs. Metronidazole, ICER. Clinical Microbiology and Infection 2014 20, 1343-1351DOI: (10.1111/1469-0691.12805) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 4 Cost-effectiveness acceptability curve. Depicts the probability that each of the three treatment strategies are cost-effective at different willingness-to-pay thresholds. Clinical Microbiology and Infection 2014 20, 1343-1351DOI: (10.1111/1469-0691.12805) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions